Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

13,314 total articles

Ultralife Corporation Reports First Quarter Results

Ultralife Corporation Reports First Quarter Results

Ultralife Corporation reported a decline in Q1 2026 revenue and profitability due to production disruptions and weaker sales in its communications systems segment, despite achieving a record backlog of $115 million. Operational challenges included power outages and inventory integration delays, impacting manufacturing efficiency and margins. The co…

AMC Global Media Inc. Reports First Quarter 2026 Results

AMC Global Media Inc. Reports First Quarter 2026 Results

AMC Global Media Inc. reported first quarter 2026 results highlighting 11% growth in streaming revenues to $174 million, driven by price increases despite a 1% decline in streaming subscribers. Total net revenues declined 2% to $542 million. The company generated $65 million in free cash flow but posted a GAAP net loss of $18.9 million, compared to…

First Advantage to Participate in Upcoming Investor Conferences

First Advantage to Participate in Upcoming Investor Conferences

First Advantage Corporation, a global software and data company specializing in identity solutions and risk management, announced that its management team will participate in several upcoming investor conferences including Needham Technology, William Blair Growth Stock, Stifel Boston Cross Sector, and Baird Global Consumer, Technology & Services. T…

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics announced the pricing of an underwritten offering of common stock and pre-funded warrants totaling approximately $300 million gross proceeds. The capital raise aims to support clinical development, including a planned Phase 3 trial of its lead AlloNK cell therapy targeting refractory rheumatoid arthritis and other autoimmune …

Brookfield Asset Management Announces Strong First Quarter Results

Brookfield Asset Management Announces Strong First Quarter Results

Brookfield Asset Management Ltd. reported robust financial results for Q1 2026, including $21 billion raised in the quarter and $67 billion year-to-date. Fee-related earnings increased 11% to $772 million for the quarter and 18% annually to $3.1 billion. The company highlights growth in infrastructure, private equity, energy, real estate, and credi…

Castellum Announces First Quarter 2026 Financial Results

Castellum Announces First Quarter 2026 Financial Results

Castellum, Inc., a cybersecurity and electronic warfare company focused on U.S. federal government contracts, announced Q1 2026 financial results showing a 23% revenue increase year-over-year to $14.3 million, improved gross profit, reduced net loss, and a debt-free balance sheet. The company also reported a record contract backlog of $273.3 millio…

AirSculpt Technologies Reports First Quarter Fiscal 2026 Results

AirSculpt Technologies Reports First Quarter Fiscal 2026 Results

AirSculpt Technologies, Inc. reported flat revenue of $39.4 million and a slight increase in case volume in Q1 2026 compared to Q1 2025, with a reduced net loss of $2.4 million. The company reaffirmed its 2026 full-year revenue guidance of $151 - $157 million and adjusted EBITDA guidance of $15 - $17 million, highlighting a strengthened balance she…

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Biotherapeutics announced positive initial clinical data from its ongoing trials of AlloNK®, an allogeneic NK cell therapy combined with rituximab, showing a 71% ACR50 response rate in refractory rheumatoid arthritis patients with six months follow-up. The therapy demonstrated a favorable safety profile enabling outpatient administration in …

KANZHUN LIMITED to Report First Quarter 2026 Results on May 20, 2026

KANZHUN LIMITED to Report First Quarter 2026 Results on May 20, 2026

KANZHUN LIMITED, a leading Chinese online recruitment platform known as BOSS Zhipin, announced it will release its unaudited consolidated results for Q1 2026 on May 20, 2026, before U.S. market open. The company will hold a conference call to discuss these results, providing investors an opportunity to gain insight into its latest operational and f…

Profusa Receives Favorable Nasdaq Listing Determination

Profusa Receives Favorable Nasdaq Listing Determination

Profusa, Inc., a digital health company specializing in tissue-integrated biosensors, announced that the Nasdaq Hearings Panel has granted their request to move their listing from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is contingent on meeting certain interim milestones, including bid price and stockholders' equity requ…

Johnson Outdoors Reports Fiscal Second Quarter Results

Johnson Outdoors Reports Fiscal Second Quarter Results

Johnson Outdoors Inc. announced robust financial results for its fiscal second quarter ended April 3, 2026, showing a 16% increase in net sales to $194.5 million and a doubling of operating income to $10.3 million year-over-year. Growth was driven by all business segments, especially Fishing and Diving, supported by improved trade conditions and ec…

6-K_GRAVITY_First QUARTER 2026 RESULT and Business Update

6-K_GRAVITY_First QUARTER 2026 RESULT and Business Update

GRAVITY Co., Ltd. announced robust first quarter 2026 results with total revenue increasing 42.7% quarter-over-quarter and net profit increasing 138.7% quarter-over-quarter. Growth was driven mainly by mobile game revenue surges tied to new launches of Ragnarok titles in Asia and Latin America, alongside increased revenues from existing games. Oper…

SCHMID Announces Investor Conference Call and Webcast

SCHMID Announces Investor Conference Call and Webcast

SCHMID Group N.V. announced an investor conference call and webcast on May 18, 2026, to discuss its annual financial results for the fiscal year ended December 31, 2025, and provide a business update. The company will file its Annual Report on Form 20-F prior to the call. The event will feature a review of financial performance followed by a Q&A se…

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

Biogen and Eisai announced that the FDA has extended the review period by three months for the supplemental Biologics License Application for LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease. The new PDUFA date is August 24, 2026. The FDA requested additional information, constituting a major…

Stellantis And Leapmotor Announce Their Intention To Take Their Strategic Partnership To The Next Level

Stellantis And Leapmotor Announce Their Intention To Take Their Strategic Partnership To The Next Level

Stellantis N.V. and Zhejiang Leapmotor Technology Co., Ltd. announced their intention to deepen their strategic partnership by increasing electric vehicle production at Stellantis' Zaragoza and Villaverde plants in Spain, leveraging joint purchasing to enhance affordability, and expanding Leapmotor International's manufacturing and sales reach in E…

Scorpio Tankers Inc. Prices Reopening of 1.75% Convertible Senior Notes due 2031 and Concurrent Stock Repurchase

Scorpio Tankers Inc. Prices Reopening of 1.75% Convertible Senior Notes due 2031 and Concurrent Stock Repurchase

Scorpio Tankers Inc. has priced a $200 million private offering of 1.75% convertible senior notes due 2031, increasing the originally planned size from $150 million. The company also announced a concurrent repurchase of approximately 649,427 shares of its common stock at $84.69 per share. Net proceeds, estimated at $216.3 million, will be used part…